RIFAMPICIN: An antibiotic with brain protective function

Brain Research Bulletin

Volumn 107, Issue , 2014, Pages 37-42

  Yulug, Burak ^a   Hanoglu, Lütfü ^a   Kilic, Ertugrul ^a   Schabitz, Wolf Rüdiger ^b  

^a ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^b Department of Physiology Brain Research Laboratory University of Istanbul Medipol ^*  (Germany)

Author keywords

Alzheimer's disease; Meningitis; Optic nerve injury; Parkinson's disease; Rifampicin; Stroke

Indexed keywords

CEFTRIAXONE; DALFOPRISTIN PLUS QUINUPRISTIN; GLUCOCORTICOID RECEPTOR; RIFABUTIN; RIFAMPICIN; NEUROPROTECTIVE AGENT; TUBERCULOSTATIC AGENT;

ACUTE DISEASE; ALZHEIMER DISEASE; BRAIN ISCHEMIA; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; MENINGITIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN; METABOLISM; OPTIC NERVE INJURIES; STROKE;

ALZHEIMER DISEASE; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BRAIN; HUMANS; MENINGITIS; NEUROPROTECTIVE AGENTS; OPTIC NERVE INJURIES; PARKINSON DISEASE; RECEPTORS, GLUCOCORTICOID; RIFAMPIN; STROKE;

EID: 84903461722     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2014.05.007     Document Type: Review

References (84)

1. Abuznait A.H., Cain C., Ingram D., Burk D., Kaddoumi A. Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J. Pharm. Pharmacol. 2011, 63:1111-1118.
2. Abuznait A.H., Patrick S.G., Kaddoumi A. Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity. J. Pharm. Pharm. Sci. 2011, 14:236-248.
3. Acocella G. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 1978, 3:108-127.
4. Adams J.D., Chang M.L., Klaidman L. Parkinson's disease - redox mechanisms. Curr. Med. Chem. 2001, 8:809-814.
5. Alvarez-Uria G., Midde M., Pakam R., Naik P.K. Initial antituberculous regimen with better drug penetration into cerebrospinal fluid reduces mortality in HIV infected patients with tuberculous meningitis: data from an HIV observational. Cohort Study. Tuberc. Res. Treat. 2013, 2013:242604.
6. Babi T., Mahovi D. Parkinson's disease-challenges in new drug development. Coll. Antropol. 2008, 32:1275-1281.
7. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann. Neurol. 1992, 31:119-130.
8. Bennett M.C. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol. Ther. 2005, 105:311-331.
9. Bi W., Zhu L., Wang C., Liang Y., Liu J., Shi Q., Tao E. Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res. 2011, 13(1395):12-20.
10. Bi W., Zhu L., Jing X., Liang Y., Tao E. Rifampicin and Parkinson's disease. Neurol. Sci. 2013, 34:137-141.
11. Böttcher T., Gerber J., Wellmer A., Smirnov A.V., Fakhrjanali F., Mix E., Pilz J., Zettl U.K., Nau R. Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J. Infect. Dis. 2000, 181:2095-2098.
12. Bowen K.K., Naylor M., Vemuganti R. Prevention of inflammation is a mechanism of preconditioning-induced neuroprotection against focal cerebral ischemia. Neurochem. Int. 2006, 49:127-135.
13. Calleja C., Pascussi J.M., Mani J.C., Maurel P., Vilarem M.J. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat. Med. 1998, 4:92-96.
14. Castagne V., Clarke P.G. Axotomy-induced retinal ganglion cell death in development: its time course and its diminution by antioxidants. Proc. Biol. Sci. 1996, 263:1193-1197.
15. Chen S., Sun Y., Zeng Z., Tao E. Rifampicin inhibits apoptosis in rotenone-induced differentiated PC12 cells by ameliorating mitochondrial oxidative stress. Neural. Regen. Res. 2010, 5:251-256.
16. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., Paul S.M., Zlokovic B.V., Piwnica-Worms D., Holtzman D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005, 115:3285-3290.
17. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 2004, 351:56-67.
18. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke, an integrated view. Trends Neurosci. 1999, 22:391-397.
19. Dutta G., Zhang P., Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol. 2008, 22:453-464.
20. Dyrks T., Dyrks E., Hartmann T., Masters C., Beyreuther K. Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem. 1992, 267:18210-18217.
21. Endoh M., Kunishita T., Tabira T. No effect of anti-leprosy drugs in the prevention of Alzheimer's disease and beta-amyloid neurotoxicity. J. Neurol. Sci. 1999, 165(1):28-30.
22. Eriksen J.L., Wszolek Z., Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch. Neurol. 2005, 62:353-357.
23. Estus S., Tucker H.M., van Rooyen C., Wright S., Brigham E.F., Wogulis M., Rydel R.E. Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. J. Neurosci. 1997, 17:7736-7745.
24. Gollapudi S., Jaidka S., Gupta S. Molecular basis of rifampicin-induced inhibition of Anti-CD95-Induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. J. Clin. Immunol. 2003, 23:11-22.
25. Hafezi-Moghadam A., Simoncini T., Yang Z., Limbourg F.P., Plumier J.C., Rebsamen M.C., Hsieh C.M., Chui D.S., Thomas K.L., Prorock A.J., Laubach V.E., Moskowitz M.A., French B.A., Ley K., Liao J.K. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 2002, 8:473-479.
26. Hal E.D., Ginsberg M., Bogousslavsky J. Antioxidant pharmacotherapy. Cerebrovascular Disease: Pathophysiology, Diagnosis and Management Malden 1997, 710-720. Blackwell, MA, USA.
27. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
28. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog. Neuropsychopharmacol. Biol Psychiatry 2008, 32:1758-1759.
29. Heisters D. Parkinson's: symptoms, treatments and research. Br. J. Nurs. 2011, 20:548-554.
30. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Buttereld D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease Proc. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3270-3274.
31. Isenmann S., Wahl C., Krajewski S., Reed J.C., Bähr M. Up-regulation of Bax protein in degenerating retinal ganglion cells precedes apoptotic cell death after optic nerve lesion in the rat. Eur. J. Neurosci. 1997, 9:1763-1772.
32. Jing X., Shi Q., Bi W., Zeng Z., Liang Y., Wu X., Xiao S., Liu J., Yang L., Tao E. Rifampicin Protects PC12 Cells from Rotenone-Induced Cytotoxicity by Activating GRP78 via PERK-eIF2α-ATF4 Pathway. PLoS One 2014, 9:e92110.
33. Karunakar N., Prabhakar M.C., Krishna D.R. Determination of antioxidant activity of some drugs using high-pressure liquid chromatography. Arzneimittelforschung 2003, 53:254-259.
34. Kilic U., Kilic E., Lingor P., Yulug B., Bähr M. Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. Acta Neuropathol. 2004, 108:65-68.
35. Kim H.S., Suh Y.H. Minocycline and neurodegenerative diseases. Behav. Brain Res. 2009, 196:168-179.
36. Kim S.K., Kim Y.M., Yeum C.E., Jin S.H., Chae G.T., Lee S.B. Rifampicin inhibits the LPS-induced expression of Toll-like Receptor 2 via the suppression of NF-kappaB DNA-binding activity in RAW 264.7 cells. Kor. J. Physiol. Pharmacol. 2009, 13:475-482.
37. Klocker N., Cellerino A., Bähr M. Free radical scavenging and inhibition of nitric oxide synthase potentiates the neurotrophic effects of brain-derived neurotrophic factor on axotomized retinal ganglion cells in vivo. J. Neurosci. 1998, 18:1038-1046.
38. Koedel U., Pfister H. Oxidative stress in bacterial meningitis. Brain Pathol. 1999, 9:57-67.
39. Kuhnke D., Jedlitschky G., Grube M., Krohn M., Jucker M., Mosyagin I., Cascorbi I., Walker L.C., Kroemer H.K., Warzok R.W., Vogelgesang S. MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides - implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007, 17:347-353.
40. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom F.J., Reiner P.B. Beta-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 2001, 76:1121-1128.
41. Langston J.W. Parkinson's disease: current and future challenges. Neurotoxicology 2002, 23:443-450.
42. Leib S.L., Kim Y.S., Chow L.L., Sheldon R.A., Täuber M.G. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to Group B Streptococci. J. Clin. Invest. 1996, 98:2632-2639.
43. Leib S.L., Kim Y.S., Ferriero D.M., Täuber M.G. Neuroprotective effect of excitatory amino acid antagonist kynurenic acid in experimental bacterial meningitis. J. Infect. Dis. 1996, 173:166-171.
44. Li J., Zhu M., Rajamani S., Uversky V.N., Fink A.L. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 2004, 11:1513-1521.
45. Limbourg F.P., Huang Z., Plumier J.C., Simoncini T., Fujioka M., Tuckermann J., Schütz G., Moskowitz M.A., Liao J.K. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J. Clin. Invest. 2002, 110:1729-1738.
46. Loeb M.B., Molloy D.W., Smieja M., Standish T., Goldsmith C.H., Mahony J., Smith S., Borrie M., Decoteau E., Davidson W., McDougall A., Gnarpe J., O'DONNell M., Chernesky M.A. randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J. Am. Geriatr. Soc. 2004, 52:381-387.
47. Lu L., Li F., Wang X. Novel anti-inflammatory and neuroprotective agents for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2010, 9:232-240.
48. Mao J. Glutamate transporter: an unexpected target for some antibiotics. Mol. Pain 2005, 9:5.
49. Mawatari K., Yasui Y., Sugitani K., Takadera T., Kato S. Reactive oxygen species involved in the glutamate toxicity of C6 glioma cells via Xc antiporter system. Neuroscience 1996, 73:201-208.
50. Mindermann T., Landolt H., Zimmerli W., Rajacic Z., Gratzl O. Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J. Antimicrob. Chemother. 1993, 31:731-737.
51. Molloy D.W., Standish T.I., Zhou Q., Guyatt G. Multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. Int. J. Geriatr. Psychiatry 2013, 28:463-470. The DARAD Study Group A.
52. Morrison A.S., Lyketsos C. The pathophysiology in Alzheimer's disease and directions in treatment. Adv. Stud. Nurs. 2005, 3(8):256-270.
53. Mustafa M.M., Ramilo O., Mertsola J., Risser R.C., Beutler B., Hansen E.J., McCracken G.H.J.R. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type b meningitis. J. Infect. Dis. 1989, 160:818-825.
54. Namba Y., Kawatsu K., Izumi S., Ueki A., Ikeda K. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet 1992, 340:978.
55. Nau R., Zysk G., Schmidt H., Fischer F.R., Stringaris A.K., Stuertz K., Brück W. Trovafloxacin delays the antibiotic-induced inflammatory response in experimental pneumococcal meningitis. J. Antimicrob. Chemother. 1997, 39:781-788.
56. Nau R., Wellmer A., Soto A., Koch K., Schneider O., Schmidt H., Gerber J., Michel U., Brück W. Rifampin reduces early mortality in experimental streptococcus pneumoniae meningitis. J. Infect. Dis. 1999, 179:1557-1560.
57. Notarianni E. Hypercortisolemia and glucocorticoid receptor-signaling insufficiency in Alzheimer's disease initiation and development. Curr. Alzheimer Res. 2013, 10:714-731.
58. Oida Y., Kitaichi K., Nakayama H., Ito Y., Fujimoto Y., Shimazawa M., Nagai H., Hara H. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Brain Res. 2006, 1082:196-204.
59. Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Mov. Disord. 2007, 22:S335-S342.
60. Philipson O., Lord A., Gumucio A., O'Callaghan P., Lannfelt L., Nilsson L.N. Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J. 2010, 277:1389-1409.
61. Psarra A.M., Bochaton-Piallat M.L., Gabbiani G., Sekeris C.E., Tsacopoulos M. Mitochondrial localization of glucocortocoid receptor in glial (Muller) cells in the salamander retina. Glia 2003, 41:38-49.
62. Qian L., Flood P.M., Hong J.S. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J. Neural. Trans. 2010, 117:971-979.
63. Qosa H., Abuznait A.H., Hill R.A., Kaddoumi A. Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J. Alzheimers Dis. 2012, 31:151-165.
64. Reynolds I.J., Hastings T.G. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J. Neurosci. 1995, 15:3318-3327.
65. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
66. Rothwell P.M. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001, 357:1612-1616.
67. Ruslami R., Ganiem A.R., Dian S., Apriani L., Achmad T.H., van der Ven A.J., Borm G., Aarnoutse R.E., van Crevel R. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect. Dis. 2013, 13:27-35.
68. Schaeffer E.L., Figueiro M., Gattaz W.F. Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo). 2011, 66(Suppl. 1):45-54.
69. Schmidt H., Zysk G., Reinert R.R., Brück W., Stringaris A., Chen V., Stuertz K., Fischer F., Bartels R., Schaper K.J., Weinig S., Nau R. Rifabutin for experimental pneumococcal meningitis. Chemotherapy 1997, 43:264-271.
70. Stuertz K., Schmidt H., Eiffert H., Schwartz P., Mäder M., Nau R. Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin/dalfopristin. Antimicrob. Agents Chemother. 1998, 42:277-281.
71. Sudlow C.L., Warlow C.P. "International Stroke Incidence Studies Colloboration" Comparable studies of the incidence of stroke and its pathological types: results from an international colloboration. Stroke 1997, 28:491-499.
72. Tomiyama T., Asano S., Suwa Y., Morita T., Kataoka K., Mori H., Endo N. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem. Biophys. Res. Commun. 1994, 204:76-83.
73. Tomiyama T., Shoji A., Kataoka K., Suwa Y., Asano S., Kaneko H., Endo N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin: Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 1996, 271:839-6845.
74. Tomiyama T., Shoji A., Kataoka K., Suwa Y., Asano S., Kaneko H., Endo N. Inhibition of Amyloid beta Protein Aggregation and Neurotoxicity by Rifampicin, Its possible function as a hydroxyl scavenger. J. Biol. Chem. 1996, 271:6839-6844.
75. Tomiyama T., Kaneko H., Kataoka Ki., Asano S., Endo N. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem. J. 1997, 322(Pt 3):859-865.
76. Trostdorf F., Reinert R.R., Schmidt H., Nichterlein T., Stuertz K., Schmitz-Salue M., Sadowski I., Brück W., Nau R. Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis. J. Antimicrob. Chemother. 1999, 43:87-94.
77. Tumani H., Smirnov A., Barchfeld S., Olgemöller U., Maier K., Lange P., Brück W., Nau R. Inhibition of glutamine synthetase in rabbit pneumococcal meningitis is associated with neuronal apoptosis in the dentate gyrus. Glia 2000, 30:11-18.
78. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., Kunert-Keil C., Walker L.C., Warzok R.W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
79. Wallerath T., Witte K., Schafer S.C., Schwarz P.M., Prellwitz W., Wohlfart P., Kleinert H., Lehr H.A., Lemmer B., Förstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13357-13362.
80. Watanabe Y., Himeda T., Araki T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med. Sci. Monit. 2005, 11:RA17-RA23.
81. Wenzel A., Grimm C., Seeliger M.W., Jaissle G., Hafezi F., Kretschmer R., Zrenner E., Remé C.E. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest. Ophthalmol. Vis. Sci. 2001, 42(7):1653-1659.
82. Xu J., Wei C., Xu C., Bennett M.C., Zhang G., Li F., Tao E. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-synuclein multimer. Brain Res. 2007, 1139:220-225.
83. Yerramasetti R., Gollapudi S., Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J. Clin. Immunol. 2002, 22:37-47.
84. Yulug B., Kilic U., Kilic E., Bahr M. Rifampicin attenuates brain damage in focal ischemia. Brain. Res. 2004, 16:76-80.